Alkermes
plc ALKS today announced positive topline results from a
phase 1 study of its new antipsychotic candidate, ALKS 3831, a
combination of a proprietary drug molecule, ALKS 33, and olanzapine, a
molecule that is commercially available under the name ZYPREXA®.
ALKS 3831 is in development for the treatment of schizophrenia, a
central nervous system (CNS) disease, and is designed to attenuate the
antipsychotic-related metabolic side effect of weight gain.
The multicenter, randomized, double-blind, placebo- and
active-controlled study was designed to compare the mean change from
baseline in body weight in 106 healthy volunteers following three weeks
of once-daily, oral administration of ALKS 3831, compared to olanzapine
alone or
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in